The Obama administration, backed by consumer groups and the American Medical Association, says these so-called “pay for delay” deals profit the drug companies but harm consumers by adding 3.5 billion annually to their drug bills.
Add to favorites Supreme Court weighs drug companies' 'pay to delay' generics policy
Add to favorites